PTPRC and neoplasm: To further evaluated the immune status in TME, the frequencies of tumor-infltrating CD4+ T cells, CD4+ Foxp3+ regulatory T cells (Tregs) and CD45+ F4/80+ macrophages were measured (online supplemental figure S6A, B, C, D).